The comparison of the curative effect on benign prostatic hyperplasia between tamsulosin and naftopidil

The comparison of the curative effect on benign prostatic hyperplasia between tamsulosin and naftopidil - The comparison between tamsulosin and naftopidil

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007763

Enrollment

Registered

2012-04-16

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

tamusulosin 12 weeks 0.2 mg once a day naftopidil 12 weeks 75 mg once a day

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: The male patients who complain of urination disorder and suitable for alfa 1 blocker treatment I-PSS total score higher than 8 and QOL score higher than 3 Maximum urinary flow rate lower than 10ml/s Total prostate volume larger than 20ml

Exclusion criteria

Exclusion criteria: Active prostate cancer or history The present illness which affect urinary condision The history of the treatment with alfa 1 blocker and/or anticholinergic drug within 4 weeks The history of the treatment with 5 alfa reductase inhibitor on benign prostatic hyperplasia The history of the surgical treatment which affect urinary condition The contraindication of alfa 1 blocker The case which the chief urologist desides not adequate for the examination

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score Urinary flow rate Residual urine	—

Countries

Japan

Contacts

Public ContactNoboru Sakamoto

Ibaraki Medical Center, Tokyo Medical University Department of Urology

uf.n.sakamoto@hotmail.com029-887-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026